Biotech Values

[WorstLuck]

Investors appear to be skeptical that the data are enough of an improvement relative to monotherapy with high-dose Eylea

The data was in line with what management was 'promoting'. The comparison to Eylea is relevant, however I think much of the move up into data and the subsequent move down is classic runup/rundown for a binary event in a company with a high percentage of retail stock ownership. It is what it is.

Let's see if anything changes tomorrow with the late breaker present with more complete data.